|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Haruo_Naito
|
|
gptkbp:collaboratedWith
|
gptkb:Biogen
gptkb:Merck_&_Co.
|
|
gptkbp:countryOfOrigin
|
gptkb:Japan
|
|
gptkbp:developedDrug
|
gptkb:Leqembi
gptkb:Dayvigo
|
|
gptkbp:focusArea
|
Neurology
Oncology
Rare diseases
|
|
gptkbp:foundedBy
|
gptkb:Toyoji_Naito
|
|
gptkbp:foundedYear
|
1941
|
|
gptkbp:headquartersLocation
|
gptkb:Tokyo,_Japan
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Eisai
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:listedOn
|
gptkb:Nikkei_225
|
|
gptkbp:marketedDrug
|
gptkb:Belviq
|
|
gptkbp:netIncome
|
~¥50 billion (varies by year)
|
|
gptkbp:notableProduct
|
gptkb:Lenvima
gptkb:Aricept
gptkb:Fycompa
gptkb:Halaven
|
|
gptkbp:numberOfEmployees
|
10,000+
|
|
gptkbp:operatesIn
|
gptkb:Europe
gptkb:Japan
gptkb:United_States
|
|
gptkbp:parentCompany
|
gptkb:Eisai_Co.,_Ltd.
|
|
gptkbp:publiclyTraded
|
Yes
|
|
gptkbp:revenue
|
~¥600 billion (varies by year)
|
|
gptkbp:stockExchange
|
gptkb:Tokyo_Stock_Exchange
|
|
gptkbp:stockSymbol
|
4523
|
|
gptkbp:subsidiary
|
gptkb:Eisai_Inc.
|
|
gptkbp:website
|
https://www.eisai.com/
|
|
gptkbp:bfsParent
|
gptkb:Biogen
gptkb:Japanese_Buddhism
gptkb:Japanese_Zen_Buddhism
gptkb:Lenvima
|
|
gptkbp:bfsLayer
|
5
|